1384 related articles for article (PubMed ID: 18855611)
1. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
5. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
6. Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
[TBL] [Abstract][Full Text] [Related]
7. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
8. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.
Deenen MJ; Cats A; Beijnen JH; Schellens JH
Oncologist; 2011; 16(6):820-34. PubMed ID: 21632461
[TBL] [Abstract][Full Text] [Related]
9. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
11. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.
Ozawa S; Soyama A; Saeki M; Fukushima-Uesaka H; Itoda M; Koyano S; Sai K; Ohno Y; Saito Y; Sawada J
Drug Metab Pharmacokinet; 2004 Apr; 19(2):83-95. PubMed ID: 15499174
[TBL] [Abstract][Full Text] [Related]
12. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
13. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
Seeringer A; Kirchheiner J
Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
[TBL] [Abstract][Full Text] [Related]
14. Ethnic differences in pharmacogenetically relevant genes.
Engen RM; Marsh S; Van Booven DJ; McLeod HL
Curr Drug Targets; 2006 Dec; 7(12):1641-8. PubMed ID: 17168839
[TBL] [Abstract][Full Text] [Related]
15. [Individualization of drug therapy and pharmacogenetics].
Yamamoto I; Azuma J
Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.
Daly AK
Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
